SARS-CoV-2 Top-Enroller Trial
Phase 3: Chicago's CCRII Enrolls
300+ Patients
Chicago Clinical Research Institute, Inc. is sharing news of
their latest successes and research developments in the
global battle against Covid-19.
As nationally accredited leaders in
the fight against Covid-19, Chicago
Clinical Research Institute has
previously collaborated with
AstraZeneca for a Covid-19
prophylaxis study.
They also worked with Sanofi on
the Covid-19 vaccine study that
helped to pave the way for the
mass vaccination rollouts which
have taken place internationally.
Now, with their latest trial,
they are proud to announce
to you their partnership with
Regeneron, a leading
biotechnology and
pharmaceutical company
based in New York.
Chicago Clinical Research
Institute believes it is
imperative that we continue to
learn from SARS-CoV-2;
understanding that the
adaptable strain may
precipitate further pandemics.
Chicago Clinical Research Institute’s recent top enroller trial used over
300 patients to test the monoclonal-antibody combination known as
AZD7442, in a single intramuscular dose.
Their findings have now been
published in The New England
Journal of Medicine and show the
monoclonal-antibody AZD7442 has
efficacy as a preexposure and post-
exposure prophylaxis.
Go to https://ccrii.us to find
out more.